Phenprocoumon Dose Requirements, Dose Stability and Time in Therapeutic Range in Elderly Patients With CYP2C9 and VKORC1 Polymorphisms

Phenprocoumon Dose Requirements, Dose Stability and Time in Therapeutic Range in Elderly Patients With CYP2C9 and VKORC1 Polymorphisms

BackgroundDose requirements of vitamin K antagonists are associated with CYP2C9 and VKORC1, but, compared to warfarin, less data is available about phenprocoumon. Furthermore, the effects on dose stability and anticoagulation quality are still unclear.MethodsAim was to scrutinize phenprocoumon dose...

Full description

Bibliographic Details
Main Authors: Katharina Luise Schneider, Melanie Kunst, Ann-Kristin Leuchs, Miriam Böhme, Klaus Weckbecker, Kathrin Kastenmüller, Markus Bleckwenn, Stefan Holdenrieder, Christoph Coch, Gunther Hartmann, Julia Carolin Stingl
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-01-01
Series:Frontiers in Pharmacology
Subjects:
CYP2C9
dose
international normalized ratio
phenprocoumon
VKORC1
time in therapeutic range
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2019.01620/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2019.01620/full

Similar Items